Today Moberg Derma AB (publ) (”Moberg Derma”) has published a supplement to the previously published prospectus regarding offer to subscribe for shares in Moberg Derma. The supplementary prospectus has been prepared due to that Moberg Derma on November 16, 2010 has been granted the permit to initiate a clinical phase II-trial for MOB-015 from the Swedish Medical Products Agency.

The supplementary prospectus, which has been approved and registered with the Swedish Financial Supervisory Authority, must be read together with the prospectus in all parts. The supplementary prospectus and the prospectus are available electronically on Moberg Derma’s website, and on E. Öhman J:or Fondkommission AB’s website,

For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35

About Moberg Derma
Moberg Derma AB, based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The Company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management. For further information, please visit:

This pressrelease:
This press release may not be announced, published or disseminated, directly or indirectly, in or into the United States of America, Australia, Japan, Canada or New Zealand.


About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit:



Documents & Links